 |
6 Diseases |  |
1 Trial |
|
1 Trial |  |
64 News |  |
- | NP-101 / Novatek Pharma
Trial initiation date: Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment (clinicaltrials.gov) - Apr 22, 2024
P1, N=18, Not yet recruiting, Sponsor: University of Florida
Initiation date: May 2024 --> Aug 2024
- | Zecuity (transdermal sumatriptan) / Teva, NP-101 / Novatek Pharma
Journal: Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. (Pubmed Central) - Feb 21, 2024
We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.
- | NP-101 / Novatek Pharma
New P1 trial: Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment (clinicaltrials.gov) - Jan 22, 2024
P1, N=18, Not yet recruiting, Sponsor: University of Florida
- || NP-101 / Novatek Pharma
Trial completion date, Trial primary completion date: BOSS-002: Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. (clinicaltrials.gov) - Jun 22, 2023
P2a/2b, N=308, Recruiting, Sponsor: Novatek Pharmaceuticals
A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients. Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Oct 2023
- || Zecuity (transdermal sumatriptan) / Teva
Review, Journal: Autism spectrum disorder in architecture perspective: a review of the literature and bibliometric assessment of research indexed in Web of Science. (Pubmed Central) - Aug 12, 2022
The study identified a massive gap in the development of literature in ASD for architecture design and built environment perspective, the most important and trending keywords are missing, and the analyses also showed a lack of subject development. The authors have suggested areas and keywords for further research to fulfill the gap in the future.
- Zecuity (transdermal sumatriptan) / Teva
Characterization of a Novel AAV Gene Replacement Therapy, VY-NPC101, In Vitro and In Vivo for the Treatment of Niemann-Pick Disease Type C1 (Poster Board Number: W-50; Hall D) - Apr 20, 2022 - Abstract #ASGCT2022ASGCT_605;
These results led to the identification of VY-NPC101. In summary, the rational design of VY-NPC101, and validation in a NPC1 disease-relevant cells lines and an NPC1 mouse model support its continued development and translation into the clinic.
- | Zecuity (transdermal sumatriptan) / Teva
Journal: Bioisosteric discovery of NPA101.3, a second generation RET/VEGFR2 inhibitor optimized for single-agent polypharmacology. (Pubmed Central) - Nov 3, 2020
Oral administration of NPA101.3 (10 mg/kg/day) completely prevented formation of tumours induced by RET/C634Y-transformed cells, while it decreased, but did not abrogate, formation of tumours induced by a control oncogene (HRAS/G12V). The balanced synchronous inhibition of both RET and VEGFR2, as well the resistance to demethylation, renders NPA101.3 a potential clinical candidate for RET-driven cancers.
- | Sofusa DoseDisc (sumatriptan succinate transdermal) - Kimberly / Clark, Zecuity (transdermal sumatriptan) / Teva, sumatriptan succinate / Generic mfg.
Journal: Transdermal Delivery of Sumatriptan Succinate Using Iontophoresis and Dissolving Microneedles. (Pubmed Central) - Sep 9, 2020
Tests, carried out with Franz diffusion cells and skin of Göttingen minipigs, showed that small decreases in the polymer concentration led to negligible lag times and marked increases in the cumulative amount of drug permeated in 6 hours (Q) and in the flux (J). At 500 μA/cm, Q and J nearly doubled for a microneedle loaded with 5% (w/w) sumatriptan and 20% (w/w) PVP (Lag Time = 0 min; Q = 2888 μg/cm; J = 490 μg/cm/h) relative to a system loaded with 5% (w/w) drug and 30% (w/w) PVP (Lag Time = 36 min; Q = 1437 μg/cm; J = 266 μg/cm/h).
- | Sofusa DoseDisc (sumatriptan succinate transdermal) - Kimberly / Clark, Zecuity (transdermal sumatriptan) / Teva, sumatriptan succinate / Generic mfg.
Journal: Experimental and Mathematical Study of the Transdermal Delivery of Sumatriptan Succinate from Polyvinylpyrrolidone-based Microneedles. (Pubmed Central) - Jul 16, 2020
The calculated diffusion coefficients were one order of magnitude greater than the value estimated when the drug was directly applied to the skin surface. The dissolution rate constant was affected by the concentration of the polymer matrix.
- | Zecuity (transdermal sumatriptan) / Teva, sumatriptan succinate / Generic mfg.
Journal: Preparation and Characterization of Micelles. (Pubmed Central) - Mar 13, 2020
In this chapter, we have discussed the protocol for the preparation of sumatriptan loaded micelles for the therapy of migraine. The inner core of these micelles comprises hydrophobic region of diblock polymer which holds the drug, while the hydrophilic region of the same provides conformational stability in the aqueous environment.
- | Zecuity (transdermal sumatriptan) / Teva
Journal: Using microemulsion as carrier for drug transdermal delivery: The effect of surfactants and cosurfactants. (Pubmed Central) - Feb 25, 2020
In the selected cosurfactant, diethylene glycol monoethyl ether (DEGMEE) showed highest permeation enhancement. Thermodynamic stability tests revealed that the experimental microemulsion was a stable enough formulation to be considered as suitable carrier for sumatriptan.
- || Zecuity (transdermal sumatriptan) / Teva
Clinical, Journal: Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. (Pubmed Central) - Nov 23, 2019
Our review identified several problems with the development, testing, approval, and marketing of the Zecuity patch. To improve the process of developing headache treatments, it is important to consider the lessons that can be drawn from an examination of this high-profile failure of the drug development and regulatory system.
- |||| Zecuity (transdermal sumatriptan) / Teva
Clinical: This is an important initiative. It will be interesting to see if additional information will be available about harms suffered by trial participants and patients from the #Zecuity #migraine patch device. (Twitter) - Mar 28, 2019
- | Zecuity (transdermal sumatriptan) / Teva
New P1 trial: Safety, Pharmacokinetic, and Tolerability Study of Zecuity (clinicaltrials.gov) - Feb 18, 2016
P1, N=37, Completed, Sponsor: NuPathe Inc.
- ||||| Zecuity (transdermal sumatriptan) / Teva
Trial initiation date: NP101-007: The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (clinicaltrials.gov) - Mar 25, 2013
P3, N=530, Completed, Sponsor: NuPathe Inc.
To improve the process of developing headache treatments, it is important to consider the lessons that can be drawn from an examination of this high-profile failure of the drug development and regulatory system. Initiation date: Jul 2008 --> Jan 2009
- ||||| Zecuity (transdermal sumatriptan) / Teva
Enrollment change: NP101-009: An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months (clinicaltrials.gov) - Apr 24, 2012
P3, N=514, Completed, Sponsor: NuPathe Inc.
Initiation date: Jul 2008 --> Jan 2009 N=400 --> 514
- Zecuity (transdermal sumatriptan) / Teva
Enrollment change: NP101-011: Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex (clinicaltrials.gov) - Apr 24, 2012
P1, N=23, Completed, Sponsor: NuPathe Inc.
N=400 --> 514 N=36 --> 23
- ||||||| Zecuity (transdermal sumatriptan) / Teva
Trial completion: NP101-009: An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months (clinicaltrials.gov) - Apr 24, 2012
P3, N=514, Completed, Sponsor: NuPathe Inc.
N=36 --> 23 Active, not recruiting --> Completed